Is HLS Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, HLS Therapeutics Inc (HLS.TO) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is HLS Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes HLS Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of HLS Therapeutics Inc?

Muslim investors may consider investing in HLS Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is HLS Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of HLS Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for HLS Therapeutics Inc updated?

The Shariah compliance status of HLS Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like HLS Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of HLS Therapeutics Inc?

You can check the latest Shariah compliance status of HLS Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

HLS.TO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 09, 2026

Report Source: 2025 Annual Report

HLS Therapeutics Inc. Stock Analysis HLS.TO

Canada Health Care Micro Cap Report: 2025 Annual

HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 86 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.

Key Statistics of HLS Therapeutics Inc (HLS.TO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

CAD4.59CAD4.67

Today's Open

CAD4.67

Volume

700.00

P/E Ratio (TTM)

52 Week Range

CAD4.22CAD5.77

Market Cap

147.30M

Avg. Volume

6505.61

Dividend Yield

Financial Metrics & Statements of HLS Therapeutics Inc (HLS.TO)

FAQ's for HLS Therapeutics Inc (HLS.TO)

According to Musaffa’s Shariah screening methodology, HLS Therapeutics Inc (HLS.TO) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.